| 14th week of 2016 patent applcation highlights part 7 |
| Patent application number | Title | Published |
|---|
| 20160095882 | TOLEROGENIC DENDRITIC CELLS FOR TREATING MYOCARDIAL INFARCTION AND MANUFACTURING METHOD THEREOF - Provided are the tolerogenic dendritic cells for treating a myocardial infarction and a method for preparing the same, and more particularly, the tolerogenic dendritic cells for treating a myocardial infarction, which can treat cardiac insufficiency that occurs by excessive remodeling of left ventricle in the heart muscle recovery process after an acute myocardial infarction, and a method for preparing the tolergenic dendritic cells. According to the present invention, the inflammatory reaction and the excessive remodeling of left ventricle in the heart muscle recovery process after a myocardial infarction can be inhibited, and thus, the incidence rate of cardiac insufficiency can be significantly reduced, thereby being effectively used for treating a myocardial infarction. | 2016-04-07 |
| 20160095883 | METHOD FOR THE TREATMENT OF OBESITY - The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject using immunotherapy to target and eliminate adipocytes. | 2016-04-07 |
| 20160095884 | METHOD FOR STABILISING SUSPENSIONS OF RED BLOOD CELLS ENCAPSULATING AN ACTIVE INGREDIENT, THE SUSPENSIONS OBTAINED - A method for obtaining a stabilised suspension of red blood cells encapsulating an active ingredient, from resealed RBCs incorporating the active ingredient, the method comprising the incubation of the resealed RBCs in an incubation solution at an osmolality of no less than 280 m Osmol/kg, for a time of 30 minutes or more, the incubation solution being a solution that does not contain an agent which is denaturating for the RBC membrane, the liquid medium is then removed from the incubated suspension and the RBCs obtained are placed in suspension in a solution allowing the injection of the suspension in a patient. The suspensions obtained are particularly characterized by an extracellular haemoglobin level maintained at 0.5 or lower, in particular 0.2 g/dl or lower and/or a haemolysis rate maintained at 2 or less, in particular 1% or less, at 72 h after placing in suspension in a preservation solution and at a temperature of between 2 and 8° C. | 2016-04-07 |
| 20160095885 | Induction Medium & Methods for Stem Cell Culture & Therapy - Novel MSC stem-cell culture and therapy methods and culture medium compositions for the purpose of inducing, activating, or priming discrete uniform cell phenotypes to selectively promote or suppress inflammation and immunity, yielding primed, activated, or induced cells used in cell-based therapy. | 2016-04-07 |
| 20160095886 | COMPOSITION FOR TREATMENT OF JOINT DISEASE AND METHOD THEREOF - The present invention provides a pharmaceutical composition comprising mesenchymal stem cells, a hyaluronan and a pharmaceutically acceptable carrier. The pharmaceutical composition is used for the treatment of the joint disease. The mesenchymal stem cells in the composition are at least one selected from the group consisting of infra-patellar fat pad stromal cells, bone marrow stem cells, Wharton's jelly stem cells and adipose derived stem cells. The concentration of the hyaluronan is in a range from 25% (v/v) to 75% (v/v). The present invention further provides a method for treating a joint disease, comprising a step of administrating a composition containing mesenchymal stem cells, a hyaluronan and a pharmaceutically acceptable carrier to an injured joint tissue of a subject. | 2016-04-07 |
| 20160095887 | MULTIPOTENT NEURAL CELLS - The inventions disclosed herein are based on the identification of novel cell populations derived from human embryonic stem cells and other pluripotent cells. The inventive cell populations may be used for cell therapies for the treatment of various neurological diseases and as substrates in pharmacological assays. | 2016-04-07 |
| 20160095888 | METHODS OF USING KRILL OIL TO TREAT RISK FACTORS FOR CARDIOVASCULAR, METABOLIC, AND INFLAMMATORY DISORDERS - This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondria respiratory chain. The present invention further includes pharmaceutical and/or nutraceutical formulations made from krill oil, methods of making such formulations, and methods of administering them to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. | 2016-04-07 |
| 20160095889 | COMPOSITION AND USE OF LACTOBACILLUS REUTERI GMNL-263 IN DECREASING BLOOD LIPID LEVELS - A use of a | 2016-04-07 |
| 20160095890 | Composition For The Treatment Of Joint Conditions - The present invention relates to a composition for improving the health status of various joints in the human body. The composition includes at least one plant extract as fatty base with active role, at least one extract from plants with anti-microbial properties, at least one extract from plants with analgesic and/or anti-inflammatory properties, and at least one extract from plants with anti-rheumatic and regenerative properties, to which dimethylsulfoxide, allantoin and/or potassium alum may be added. The composition may be used to treat osteoarthritis, rheumatic joint disease, joint swelling, pain, hallux valgus, traumatic conditions of the joints including sprains, strains, post-surgical recovery, bone edema, and speed up the recovery of athletes post-injury. | 2016-04-07 |
| 20160095891 | COMPOSITION FOR PREVENTING AND TREATING INFLAMMATORY DISEASE, CONTAINING OIL OF LITSEA JAPONICA AS ACTIVE INGREDIENT, AND METHOD FOR PREPARING SAME - The present invention relates to a composition for an inflammatory disease, using Litsea japonica, and more specifically to a composition for preventing and treating an inflammatory disease, containing the oil derived from the fruits or the seeds of Litsea japonica, and a method for preparing the same. The present invention uses the fruits (excluding the seeds) or the seeds of Litsea japonica and obtains the oil, which is used as an active ingredient of a composition for preventing and treating an inflammatory disease, by using n-hexane, wherein the oil is obtained by: separating the fruits (excluding the seeds) of Litsea japonica from the seeds; injecting n-hexane, which is a solvent, into the fruits (excluding the seeds) or the seeds, 9-11 times greater than the weight of each: stirring the same for 24 hours at room temperature and extracting the same; and removing a hexane layer. | 2016-04-07 |
| 20160095892 | Sour Cherry Topical Biotherapeutic Formulations, Method of Manufacture and Method of Treatment of Human Osteoarthritis Symptoms - A biotherapeutic anti-inflammatory composition, its method of manufacture and method of treatment of various diseases, the composition having an efficacious amount of solid sour cherry seed extract and sour cherry seed oil sufficient to inhibit production of disease-associated inflammatory cytokines by CD3+ T lymphocytes in a vertebrate mammal. | 2016-04-07 |
| 20160095893 | PLANT-DERIVED FORMULATIONS FOR TREATMENT OF HIV - Disclosed herein are methods for treating mammals with HIV/AIDS comprising administering a therapeutically effective amount of a composition comprising an extract of | 2016-04-07 |
| 20160095894 | DIETETIC MULTI-COMPONENT SYSTEM - An improved multi-component system containing a main component and at least one additional component that is physically separated from the main component, and a use of the system as a food supplement and a pharmaceutical product. | 2016-04-07 |
| 20160095895 | HIGHLY CONCENTRATED FORMULATIONS OF SOLUBLE Fc RECEPTORS - The present invention relates to novel formulations of soluble Fc receptors and especially to formulations containing high concentrations of soluble FcγRIIB receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved. | 2016-04-07 |
| 20160095896 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS - The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production. | 2016-04-07 |
| 20160095897 | PAR-4 ANTAGONISTS FOR USE IN THE TREATMENT OR PREVENTION OF INFLUENZA VIRUS TYPE A INFECTIONS - The present invention provides methods and compositions (such as pharmaceutical compositions) comprising PAR4 antagonists for treating or preventing influenza virus type A infections, in particular H1N1 infection. PAR4 antagonists may be combined with a PAR2 agonist or a PAR1 antagonist. | 2016-04-07 |
| 20160095898 | YERSINIA OUTER PROTEIN M (YOPM) IN THE TREATMENT OF PSORIASIS - The present invention relates to the use of | 2016-04-07 |
| 20160095899 | Allergen Peptide Fragments and Use Thereof for Treatment of Birch Pollen Allergies - The present invention relates generally to in vivo methods and compositions designed for allergen specific immunotherapy. The compositions include contiguous overlapping peptide fragments which together form an entire amino acid sequence of an allergen. | 2016-04-07 |
| 20160095900 | Human fertility enhancement with cortisol reduction food - A method of using a fertility enhancement food to improve human fertility. This fertility enhancement food consists of transfer factor, lactic acid generating bacteria, and/or glucans in appropriate combinations. The fertility food, administered correctly, reduces cortisol levels. High cortisol interferes with conception and stable pregnancies. Dosage amounts are adjusted for client weight. Consumption frequency may be adjusted in response to cortisol measurements. Typically, consumption of the fertility food begins seven or more days before planned conception. | 2016-04-07 |
| 20160095901 | LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOF - The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods. | 2016-04-07 |
| 20160095902 | Auris Formulations for Treating Otic Diseases and Conditions - Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures. | 2016-04-07 |
| 20160095903 | EXTENDED RELEASE OF NEUREGULIN FOR IMPROVED CARDIAC FUNCTION - The present invention provides extended release compositions comprising neuregulin for preventing, treating or delaying various diseases or disorders. The present invention also provides methods for preventing, treating or delaying various diseases or disorders by extended release of neuregulin. | 2016-04-07 |
| 20160095904 | STABILIZED LIQUID FORMULATION - The present invention relates to a liquid formulation comprising an active substance and protamine, wherein the liquid formulation differs from a suspension. | 2016-04-07 |
| 20160095905 | Compositions and Methods for Induced Brown Fat Differentiation - The invention provides methods and compositions for inducing brown fat cell differentiation through modulation of both Prdm1β and C/EBPβ activity and/or expression. Also provided are methods for preventing or treating obesity or an obesity related disorder in a subject through stimulation of both Prdm1β and C/EBPβ expression and/or activity. Further provided are methods for identifying compounds that are capable of modulating both Prdm1β and C/EBPβ expression and/or activity. | 2016-04-07 |
| 20160095906 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID-LABILE DRUGS - An enteric-coated oral dosage form comprising an acid labile active pharmaceutical ingredient where the composition is substantially free of monomeric phthalic acid esters and synthetic oils is described herein. Also provided are methods for making and using the enteric-coated oral dosage form. The disclosed pharmaceutical compositions comprise an enteric coating which includes at least one plasticizer, at least one film-forming agent and optionally at least one anti-sticking agent. | 2016-04-07 |
| 20160095907 | PLANT CELL CULTURE EXPRESSING HUMAN LYSOSOMAL PROTEINS AND USES THEREOF - A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases. | 2016-04-07 |
| 20160095908 | Botulinum Toxin for Primary Disorders of Mood and Affect using Neurotransmitter CNS imaging Studies - The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety, and sleep disorders and CNS disorders comprising the administration of a neurotoxin. | 2016-04-07 |
| 20160095909 | Methods of Preventing Rejection of Transplanted Tissue by Administering Anti-CD40L Antibody and Dendritic Cells Loaded with Type B Peptide - A method is provided for preventing rejection by an immune system of a recipient subject of a tissue transplanted from a donor subject into the recipient subject without the need for long-term administration of non-specific immunosuppressive drugs. | 2016-04-07 |
| 20160095910 | SELF-ASSEMBLING SYNTHETIC PROTEINS - The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host. | 2016-04-07 |
| 20160095911 | APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES - The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer. | 2016-04-07 |
| 20160095912 | APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES - The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer. | 2016-04-07 |
| 20160095913 | Controlled Release Vaccines and Methods of Treating Brucella Diseases and Disorders - Methods and compositions for the treatment of | 2016-04-07 |
| 20160095914 | Adenylate Cyclase Deficient Bordetella Strains - A CyaA-deficient | 2016-04-07 |
| 20160095915 | INTERACTIONS OF BETANODAVIRUSES IN INFECTION - Disclosed are interactions between different betanodaviruses during infection of cells “in vitro” and in European sea bass. More specifically, fish administered striped jack nervous necrosis viruses (SJNNV), which are then exposed to red-spotted grouper nervous necrosis viruses (RGNNV), have fewer symptoms of disease associated with RGNNV and/or increased survival as compared to fish not administered SJNNV prior to exposure to RGNNV. | 2016-04-07 |
| 20160095916 | INDUCTION OF CROSS-REACTIVE CELLULAR RESPONSE AGAINST RHINOVIRUS ANTIGENS - The present invention concerns: a) an isolated peptide comprising an amino acid sequence which is at least 90% identical to the VP4 amino acid sequence of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and/or b) an isolated peptide comprising an amino acid sequence of at least 100 amino acids which is at least 90% identical to an amino acid sequence located in the last 363 C-terminal amino acids of the RNA polymerase of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and c) a Th1 adjuvant when said immunogenic composition comprises one or more of said isolated peptides. | 2016-04-07 |
| 20160095917 | DPS FUSION PROTEINS FOR USE IN VACCINES AND DIAGNOSTICS - Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products. | 2016-04-07 |
| 20160095918 | RAPID, EFFICIENT PURIFICATION OF HSV-SPECIFIC T-LYMPHOCYTES AND HSV ANTIGENS IDENTIFIED VIA SAME - A method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 2016-04-07 |
| 20160095919 | THERAPEUTIC AGENT FOR NEUROLOGICAL DISORDER - Provided is a therapeutic agent for a neurological disorder directly acting on oxygen concentration-dependent vascular barrier breakdown. The therapeutic agent for a neurological disorder contains any one of (a) a functional nucleic acid against ADAM (a disintegrin and metalloproteinase)12 or ADAM17, (b) a functional nucleic acid expression vector containing a DNA encoding the functional nucleic acid (a) and (c) a neutralizing antibody against ADAM12 or ADAM17, as an active ingredient. The functional nucleic acid is preferably siRNA. It is preferable that the functional nucleic acid against ADAM12 is siRNA consisting of a sense strand sequence of nucleotides represented by SEQ ID NO: 1 or 3 and an antisense strand sequence complementary thereto or that the functional nucleic acid against ADAM17 is siRNA consisting of a sense strand sequence of nucleotides represented by SEQ ID NO: 5 or 7 and an antisense strand sequence complementary thereto. | 2016-04-07 |
| 20160095920 | KRAS MUTATIONS AND RESISTANCE TO ANTI-EGFR TREATMENT - The disclosure provides compositions and methods for detecting and predicting acquired resistance to anti-EGFR treatment in colorectal cancers. Also provided are compositions and methods of preventing, reversing or delaying the acquired resistance. The present disclosure also provides kits for use in the methods described herein. | 2016-04-07 |
| 20160095921 | Combinations and Methods for Treating Inflammatory Bowel Disease Using a Combination Therapy of Small Molecule Inhibitors of C-C Chemokine Receptor 9 (CCR9) and Anti-alpha4beta7 Integrin Blocking Antibodies - Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-α4β7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-α4β7 integrin antibody. | 2016-04-07 |
| 20160095922 | SELECTIVE RESONANCE OF BODILY AGENTS - Chemical compositions may be selectively or preferentially excited by the application of scores comprising a series of energy inputs. | 2016-04-07 |
| 20160095923 | ORAL COMPOSITION COMPRISNG (+)-CATECHIN - The invention relates to a gastroenteric composition comprising a compound of monomeric (+)-catechin and at least one basic amino acid or at least one derivative of a basic amino acid, said compound being in the form of a complex having a molar equivalence ratio of said monomeric (+)-catechin to said at least one basic amino acid or its derivative of between 1:1 and 1:2.5, preferably between 1:1 and 1:2. | 2016-04-07 |
| 20160095924 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS - The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. | 2016-04-07 |
| 20160095925 | STABLE FORMULATION OF AZACITIDINE OR SALTS THEREOF AND THEIR PROCESS FOR PREPARATION - The present invention relates to a stable pharmaceutical composition comprising azacitidine or its pharmaceutically acceptable salts, one or more sugar alcohols and one or more pharmaceutically acceptable excipients, wherein said composition is suitable for parenteral administration. The invention also relates to processes for preparing the preparation of such reconstitutable formulations. The invention also relates to therapeutic methods of use of such formulations and to use of such formulations in the manufacture of medicaments. | 2016-04-07 |
| 20160095926 | DEVICE FOR TRANSDERMAL ADMINISTRATION OF DRUGS INCLUDING ACRYLIC BASED POLYMERS - A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent. | 2016-04-07 |
| 20160095927 | Ophthalmic Compositions Containing A Synergistic Combination of Two Polymers - Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity. | 2016-04-07 |
| 20160095928 | COMPOSITION FOR HOT MELT EXTRUSION AND METHOD FOR PRODUCING HOT MELT EXTRUDATE BY USING SAME - Provided is a composition for hot melt extrusion including a drug and hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more and a mole ratio of an acetyl group to a succinyl group of less than 1.6. Further, provided is a method for producing a hot melt extrudate including the step of hot melt-extruding a composition for hot melt extrusion including a drug and hypromellose acetate succinate having a molar hydroxypropoxy substitution of 0.40 or more and a mole ratio of an acetyl group to a succinyl group of less than 1.6, at a hot melt temperature of not lower than a melting temperature of the hypromellose acetate succinate or of not lower than a temperature at which both the hypromellose acetate succinate and the drug are melted. | 2016-04-07 |
| 20160095929 | PROMOTION OF WOUND HEALING - The present invention provides compositions and methods that promote wound healing in a subject with a cutaneous injury. In particular, the present invention provides systemic and/or local administration of one or more compositions that cause ganglioside depletion (e.g., glucosylceramide synthase (GCS) inhibitors) for the treatment of cutaneous wounds. | 2016-04-07 |
| 20160095930 | Derivatisation of Granulocyte Colony-Stimulating Factor - The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds. | 2016-04-07 |
| 20160095931 | COMPOSITIONS CONTAINING HC-HA COMPLEX AND METHODS OF USE THEREOF - Disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of IαI, wherein the transfer of the heavy chain of IαI is catalyzed by TSG-6. Further disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of IαI, wherein the transfer of the heavy chain of IαI is catalyzed by the TSG-6 like protein. Additionally, disclosed herein are methods of manufacturing said complex and methods of use thereof. | 2016-04-07 |
| 20160095932 | Bone Targeted Therapeutics and Methods of Making and Using the Same - The present invention provides novel bisphosphonate conjugates, pharmaceutical compositions comprising bisphosphonate conjugates and methods of using such analogs in the treatment of bone cancer, bone-related diseases, bone infection, bone inflammation, and diseases of the soft tissues surrounding bones. | 2016-04-07 |
| 20160095933 | WATER SOLUBLE POLYCARBONATES FOR MEDICAL APPLICATIONS - Water soluble biodegradable polymers were prepared by an organoacid catalyzed ring opening polymerization (ROP) of a cyclic carbonate monomer bearing an active ester side chain. The initial polymer comprising an active ester side chain was treated with an amino-alcohol, which transformed the active ester groups to N-substituted amide groups bearing mono-hydroxy alkyl groups and/or dihydroxy alkyl groups, thereby forming the water soluble polymers. The water-soluble polymers are non-toxic and exhibit stealth properties in buffered serum solution. | 2016-04-07 |
| 20160095934 | DASATINIB AND NONLINEAR CONFIGURATION POLYETHYLENE GLYCOL CONJUGATE - A dasatinib and nonlinear configuration polyethylene glycol conjugate represented by formula I, wherein core is the core structure of a nonlinear configuration of polyethylene glycol, selected from a residue of pentaerythritol, methylglucoside, sucrose, diethylene glycol, propanediol, glycerol or polyglycerol removaed the hydrogen atom from the hydroxyl group; P is a polyethylene glycol residue with a number-average molecular weight of 300-60000 Da; X is selected from single bond, —CH | 2016-04-07 |
| 20160095935 | CONJUGATES COMPRISING MANNAN AND MYELIN BASIC PROTEIN (MBP) - A first aspect of the invention relates to a conjugate including mannan and at least one epitope comprising a peptide fragment of a protein selected from myelin basic protein (MBP), myelin oligodentrocyte glycoprotein (MOG) and proteolipid protein (PLP), said peptide fragment being in linear or cyclic form; and wherein said epitope is linked to mannan via a [(Lys-Gly) | 2016-04-07 |
| 20160095936 | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF - Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide. Depending on the cargo, the length and compositions of the polar block can be tailored to push the equilibrium toward albumin binding, stable micelle formation, or cell insertion. The conjugates can be administered to a subject, for example, a subject with cancer or an infection, to induce or enhance a robust immune response in the subject. | 2016-04-07 |
| 20160095937 | INTERFERING RNA DELIVERY SYSTEM AND USES THEREOF - The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided. | 2016-04-07 |
| 20160095938 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS - The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an aldehyde group obtained from oxidation of a 2-hydroxyethylamine moiety on the CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention. | 2016-04-07 |
| 20160095939 | NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES - The present invention concerns improved methods and compositions for neoadjuvant use of antibody-drug conjugates (ADCs) in cancer therapy, preferably ADCs comprising an anthracycline or camptothecin, more preferably SN-38 or pro-2-pyrrolinodoxorubicin (P2PDox). The ADC is administered as a neoadjuvant, prior to treatment with a standard anti-cancer therapy such as surgery, radiation therapy, chemotherapy, or immunotherapy. Neoadjuvant use of the ADC substantially improves the efficacy of standard anti-cancer therapy and may debulk a primary tumor or eliminate micrometasteses. In most preferred embodiments, neoadjuvant ADC in combination with a standard anti-cancer therapy is successful in treating cancers that are resistant to standard treatments, such as triple-negative breast cancer (TNBC). | 2016-04-07 |
| 20160095940 | CARBON NANOTUBE NANO-THERAPY COMPOSITES WITH PACLITAXEL - In various embodiments a payload molecule or drug molecule delivery system is disclosed for delivering paclitaxel. The system comprises a plurality of functionalized discrete carbon nanotubes having specific properties. The composition can comprise a plurality of discrete carbon nanotubes that have at least a portion of the carbon nanotubes with a number average (ratio of number average contour length to end to end length) of greater than 1.1 and up to about 3. These discrete carbon nanotubes having the specified ratio of number average (tube contour length (T | 2016-04-07 |
| 20160095941 | ENHANCED LOADING OF INTACT, BACTERIALLY DERIVED VESICLES WITH SMALL MOLECULE COMPOUNDS - Enhanced loading of small molecule compounds into intact, bacterially derived vesicles provides operational and therapeutic advantages. | 2016-04-07 |
| 20160095942 | CARRIER-ANTIBODY COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. | 2016-04-07 |
| 20160095943 | Visualization of Foreign Bodies in Tissue - Agents and methods for visualization and removal of foreign material from tissue have been described. The techniques include selection of an appropriate visualization agent, treating the wound with the visualization agent and observing the wound, illuminating the wound with lighting specific to the particular visualization agent and material and viewing the illuminated wound through an optical filter specific to the wavelength of light emitted by the visualization agent. | 2016-04-07 |
| 20160095944 | NOVEL MULTIMODAL CT/OPTICAL AGENTS - The present application relates to compositions comprising an iodinated contrast agent and indocyanine green co-encapsulated inside a liposomal carrier, various uses thereof as well as methods for their preparation. | 2016-04-07 |
| 20160095945 | USE OF NON-LABELED SUGARS AND DETECTION BY MRI FOR ASSESSING TISSUE PERFUSION AND METABOLISM - A method for magnetic resonance (MR) imaging or spectroscopy on a MR scanner to detect tissue physiological parameters in one or more tissue areas in a human or non-human subject includes administering to the subject a contrast enhancing physiologically tolerable amount of a sugar that is non-labeled, subjecting the subject to an MR procedure capable of generating MR signals encoding at least one tissue area in the subject in which the sugar either passes or is taken up, detecting a temporal variation in the MR signals in the at least one tissue area after the administering the sugar, determining at least one tissue-related parameter from the temporal variation, and ascertaining whether the at least one tissue-related parameter is abnormal. | 2016-04-07 |
| 20160095946 | LABELLED CARBOXYLIC ACIDS AND THEIR USES IN MOLECULAR IMAGING - The present invention pertains generally to the field of imaging compounds, and more specifically to certain 2,2-dialkyl radionuclide-labelled carboxylic acids suitable for PEWT, SPECT and/or DNP imaging. Also described are uses of such compounds in the imaging of, inter alia, cancer tumors, metastasis, Alzheimer's disease and multiple sclerosis. | 2016-04-07 |
| 20160095947 | METHOD AND DEVICE FOR DISINFECTING AND PERFUMING OF SPACES AND SURFACES - A method for the disinfection of spaces and surfaces, including the steps of preparing a diffuser device equipped with a tank containing a liquid solution and nebulising means associated with the tank and designed for drawing out the liquid solution from the tank spraying it in the space, nebulising in the room a predetermined quantity of liquid solution for an interval of time and subsequent nebulising in the room a predetermined quantity of a liquid substance, different from the liquid solution and having a predetermined fragrance, following an interval of time. | 2016-04-07 |
| 20160095948 | SANITIZING DEVICE FOR TOOL AND CART HANDLES - The sanitizing device for tool and cart handles is designed to rest on a base mount attached to the tool handle. When the user wants to use the sanitizing device they move the device from its rest position, spray sanitizing solution onto the desired surface area of the tool or cart handle, then slide the device along the handle to sanitize and/or disinfect it. The device includes a sponge which aids in the thorough sanitization of the desired surface area. In addition to sanitizing tool or cart handle, the device allows the user to direct the sanitizing spray into their hands to eliminate or minimize the transfer or spread of communicable pathogens. The fluid reservoir may be refillable or, alternatively, the fluid reservoir may be disposable and replaceable when the fluid is depleted. | 2016-04-07 |
| 20160095949 | ATOMIZING STERILIZATION OF A PLURALITY OF CLEANING AGENTS - A method for multi-agent dry fogging. The method includes pressurizing a first agent to a first range of pressure. The first agent includes a sterilant. The method also includes pressurizing a second agent to a second range of pressure. The second agent includes a non-depleting solution for protection against microorganism growth. The method also includes pressurizing a gas to a gas range of pressure. The method also includes atomizing the first agent at a nozzle to mix with the pressurized gas in a first application stage to disperse the first agent in a first dry fog within an ambient environment. The method also includes atomizing the second agent at the nozzle to mix with the pressurized gas in a second application stage to disperse the second agent in a second dry fog within the ambient environment. | 2016-04-07 |
| 20160095950 | Method and apparatus to dispense fragrance into the air in a bowling structure - A method to condition the air in a bowling alley utilizes an oil mixture which is dispensed by conditioning apparatus which down and up a synthetic bowling lane. The oil mixture comprises original lane oil and a fragrance composition which admixed to the oil mixture to produce a fragrant lane oil which has at 1700 cm | 2016-04-07 |
| 20160095951 | ION EXCHANGE ABSORBENT SYSTEMS, APPARATUSES, AND METHODS - Systems, methods, and apparatuses for increasing liquid absorption are described. Some embodiments may include a dressing having an absorbent layer containing super-absorbent material as well as ionic-exchange media (IEM). In some embodiments, the absorbent layer may include absorbent fibers. The absorbent fibers may each include a super-absorbent core surrounded by a water-permeable layer onto which ionic-exchange media (IEM) may be grafted. As liquid comes into contact with the IEM, its ionic nature may be reduced, therefore protecting the absorbent qualities of the super-absorbent material. | 2016-04-07 |
| 20160095952 | ARTICLE WITH TACKIFIER-FREE ADHESIVE - Disposable absorbent articles assembled from a collection of components using an adhesive comprising an amorphous polyolefin composition and a heterophase polyolefin composition comprising amorphous character and crystalline blocks. | 2016-04-07 |
| 20160095953 | HEMOSTATIC DEVICE - A hemostatic device, method of making, and method of using for internal and external applications to wounds in the body of a patient to induce hemostasis at an anatomical site. | 2016-04-07 |
| 20160095954 | FIBRIN MICROTHREADS - Compositions that include fibrin microthreads are provided. The compositions can include one or more therapeutic agents including cytokines and interleukins, extracellular matrix proteins and/or biologically active fragments thereof (e.g., RGD-containing peptides), hormones, vitamins, nucleic acids, chemotherapeutics, antibiotics, and cells. Also provided are methods of making compositions that include fibrin microthreads. Also provided are methods for using the compositions to repair or ameliorate damaged or defective organs or tissues. | 2016-04-07 |
| 20160095955 | PLIABLE MEDICAL DEVICE AND METHOD OF USE - A firm but pliable medical device for use as a bone graft substitute or bone graft extender retains its shape without the requirement of a containment device, such as a syringe. Because the device is solid, it is easy to locate or position in-vivo and, in the moist environment of the body, it will hold its shape well, for an extended time. Because the lyophilized pliable medical device is porous, it adsorbs blood and other beneficial cells containing body fluids, such as bone marrow, contributing to its superior bone repair efficacy in comparison to an analogous putty that has not been lyophilized. In addition these lyophilized pliable medical devices are easier to terminally steam sterilize than the analogous putty because there is no moisture present to boil and ‘blow-out’ of the containment device (syringe). The glycerin that is present in the formulation lends pliability but has a low vapor pressure. | 2016-04-07 |
| 20160095956 | IMPLANT AND METHOD OF PRODUCING AN IMPLANT - The invention provides a method for producing an implant from interstitial, connective or supporting tissue, the method comprising at least one step of perfusing the tissue with at least one decellularisation medium under negative pressure applied for substantially the whole time period of the perfusion. | 2016-04-07 |
| 20160095957 | METHOD FOR PREPARING BIOLOGICAL TISSUES FOR USE IN BIOLOGICAL PROSTHESES - A method of treating a biological tissue for biological prostheses includes steps of fixation of the biological tissue via a fixing solution including glutaraldehyde and detoxification of the fixed biological tissue via treatment with a detoxifying solution. The detoxification step includes one or both of eliminating phospholipids via treatment with an elimination solution and a treatment with a detoxifying solution. The elimination solution includes 1,2-octanediol and ethanol. The detoxifying solution includes taurine or homocysteic acid. | 2016-04-07 |
| 20160095958 | BONE REGENERATION USING STROMAL VASCULAR FRACTION, PLATELET-DERIVED GROWTH FACTOR-RICH HYDROGEL, THREE-DIMENSIONAL PRINTED POLY-EPSILON-CAPROLACTONE SCAFFOLDS - The presently disclosed subject matter focuses on recapitulating the heterotypic interactions needed to maximize the co-development of vasculature and bone. More particularly, the presently disclosed subject matter explores the potential of cellular aggregation and temporal presentation of factors to induce the cell-cell signaling events required to stimulate ASCs to self-organize into vascularized bone. Further, exogenous PDGF-BB synergizes complex tissue formation in ASC cultures by enhancing vascular stability and osteogenic differentiation. The presently disclosed approach provides a robust protocol to engineer vascularized bone with ASCs in vitro. | 2016-04-07 |
| 20160095959 | MODULAR FABRICATION SYSTEMS AND METHODS - The present invention relates to an article fabrication system having a plurality of material deposition tools containing one or more materials useful in fabricating the article, and a material deposition device having a tool interface for receiving one of the material deposition tools. A system controller is operably connected to the material deposition device to control operation of the material deposition device. Also disclosed is a method of fabricating an article using the system of the invention and a method of fabricating a living three-dimensional structure. | 2016-04-07 |
| 20160095960 | Coating Formulations for Scoring or Cutting Balloon Catheters - The present invention is related to scoring or cutting balloon catheters carrying at least on a portion of their surface at least one drug or drug preparation and at least one lipophilic antioxidant at a ratio of 3-100% by weight of the at least one lipophilic antioxidant in relation to 100% by weight of the drug, wherein a combination of the at least one drug being a limus drug and the at least one lipophilic antioxidant being butylated hydroxytoluene is excluded. | 2016-04-07 |
| 20160095961 | CROSSLINKED COATINGS DELIVERED BY A BALLOON - The present invention relates to systems for and corresponding methods of delivering a therapeutic agent to a vessel wall of a body lumen by providing a compound capable of being crosslinked after intraluminal release onto a vessel wall so that the therapeutic agent is temporarily retained at the site of delivery by the crosslinked compound. | 2016-04-07 |
| 20160095962 | ADHESION PREVENTING MATERIAL - An object of the present invention to provide an antiadhesive material designed to have time-varying fluidity as it exhibits a gel form of high fluidity at the time of administration, and exhibits a gel form of low fluidity after it is administered to an incised and sutured site. A powdery antiadhesive material to be mixed with an aqueous solvent upon use containing alginic acid and/or a salt thereof, that is configured to be mixed with the aqueous solvent upon use so that the viscosity at 37° C. is less than or equal to 70 mPas·s at the time of 5 minutes after mixing with the aqueous solvent, and the viscosity at 37° C. is more than or equal to 120 mPas·s at the time of 60 minutes after mixing, will have high fluidity at the time of administration when it is mixed with an aqueous solvent upon use in a clinical scene, and have low fluidity after it is administered to an incised and sutured site, and thus is capable of satisfying both the excellent operability and the antiadhesive effect. | 2016-04-07 |
| 20160095963 | METHODS AND COMPOSITIONS FOR TREATING POST-OPERATIVE PAIN COMPRISING CLONIDINE - The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days. | 2016-04-07 |
| 20160095964 | IRRIGATION FLUID CONTAINMENT SYSTEMS - Various irrigation fluid containment systems and components are disclosed. In some embodiments, the irrigation fluid containment system comprises a medical kit and/or an irrigation kit. In some embodiments, the irrigation fluid containment system comprises a medical basin and/or an irrigation basin. In some embodiments, the irrigation fluid containment system comprises an irrigation shield. In some embodiments, the irrigation fluid containment system comprises a suction hose. | 2016-04-07 |
| 20160095965 | INSTRUCTIONAL MEDICAL TREATMENT SYSTEM - The present invention discloses an appliance for administering medical treatment to a person, as well as methods of using the appliance. In various embodiments, the appliance may be comprised of a medical device, an electronic processor, an electronic display (such as a liquid crystal display (LCD)), an audio output device (such as a piezoelectric speaker/microphone), electronic controls for controlling the operation of the electronic processor, and an electronic input receptacle (such as a DVD drive or USB port) adapted to receive and electronically access an electronic storage device (such as a DVD or flash memory device). The electronic processor or electronic storage device or both have information related to use and operation of the medical device digitally stored therein, so that the user of the appliance has ready access to instructional materials. Thus, the appliance includes an internal system for instructing the user in the use of the medical device. | 2016-04-07 |
| 20160095966 | NEGATIVE PRESSURE DEVICE - A method and apparatus are disclosed for providing negative pressure at a wound site. The apparatus includes a negative pressure reservoir and a reservoir valve for selectively connecting the reservoir to a wound chamber at a wound site. In particular, but not exclusively, the present invention relates to an apparatus including a source of negative pressure which acts as a negative pressure reservoir to continually or repeatedly “top up” an applied negative pressure so that negative pressure applied at a wound site can be maintained within desired limits for a relatively long period of time. | 2016-04-07 |
| 20160095967 | HANDS FREE BRA KIT FOR REMOVING MILK FROM THE HUMAN BREAST - The present invention provides hands free bra kit for removing milk from the human breast comprising an adjustable neck strap, a bottom strap, a top strap a pair of loops, a pair of tension balls and a reinforced area. The hands free bra kit is a fully portable and compact kit. The neck strap is provided around the neck, the top strap is provided around top of breast shed and the bottom strap is provided around the waist. The loop is configured for inserting horn of the breast and the tension ball holds an encircled material on the breast horn. The reinforced area can be a thicken portion or a grommet designed to take the weight of the bra kit. A method for placing hands free kit on breast and method for massaging breast to remove the milk completely is also disclosed. | 2016-04-07 |
| 20160095968 | Back Up Controller System With Updating - A medical device system includes a medical device configured to be carried by a patient and a plurality of controllers capable of controlling operation of the medical device. Each controller has an active state in which the controller is in communication with, and controls the operation of, the medical device, and a passive state in which the controller is not controlling operation of the medical device. At any given time only one of the plurality of controllers will be in the active state and a remainder of the plurality of controllers will be in the passive state. The active controller may be configured to continually communicate with the remainder of passive controllers, without using the medical device as an intermediary, to update the information stored in the memories of the passive controllers to match the information in the memory of the active controller. | 2016-04-07 |
| 20160095969 | OXYGENATOR MODULE, OXYGENATOR AND PRODUCTION METHOD - An oxygenator module for gas exchange between blood and a gas in an extracorporeal lung support system, with several layers of semipermeable, gas-perfusable hollow fibers, wherein the hollow fibers of one of the layers are oriented at an angle of rotation about a central longitudinal axis of the oxygenator module with respect to the hollow fibers of another one of the layers, and with a potting which extends along the central longitudinal axis and in which the hollow fibers are fixed, wherein the potting defines a cavity that extends along the central longitudinal axis and in which the hollow fibers are arranged and which is blood-perfusable in the direction of the central longitudinal axis, wherein the potting has an essentially circular inner sheath surface that limits the cavity radially outward: as well as a method for producing the oxygenator module. | 2016-04-07 |
| 20160095970 | RENAL THERAPY BLOOD CLEANSING SYSTEM WITH SELECTIVE VALVE FEATURE - A renal therapy blood cleansing system is provided. The renal therapy blood cleansing system includes a blood circuit including a blood filtering device, a therapy fluid circuit including a balance chamber configured to exchange like volumes of fresh and used therapy fluid, a first pump configured to pump fresh therapy fluid to the balance chamber, a second pump configured to pump used therapy fluid to the balance chamber, and at least one valve located downstream from the balance chamber, the at least one valve enabling fresh therapy fluid from the balance chamber to be directed selectively to (i) a flow path leading to an inlet of the blood filtering device, or (ii) a flow path leading to the blood circuit at a location upstream or downstream of the blood filtering device. | 2016-04-07 |
| 20160095971 | METHOD AND DEVICE FOR MONITORING EXTRACORPOREAL BLOOD FLOW - A method and a device for monitoring an extracorporeal blood flow during an extracorporeal blood treatment with an extracorporeal blood treatment device. The extracorporeal blood treatment device may include the device for monitoring an extracorporeal blood flow. The arterial and/or venous patient access is monitored with a first and a second method, each of which there is a check for a presence of at least one criterion that is characteristic of a condition of the vascular access that is not in proper order, the criteria for the first and second methods being distinguished from one another. A blood pump, which is preferably an occlusion blood pump, is stopped once the presence of the at least one criterion of the first method has been established, while a venous cut-off unit remains open. Once the blood pump has been stopped, the presence of the at least one criterion is checked with the second method. The venous cut-off unit is not closed until the at least one criterion for the second method is present. Otherwise the blood pump is restarted to continue the blood treatment. | 2016-04-07 |
| 20160095972 | COAXIAL VENAL CANNULA - A dual lumen cannula includes a first tube defining a return lumen and having a proximal end, a mid-portion and a distal end, wherein the distal end includes a return aperture. A second tube is coaxial with the first tube and has a proximal end and a distal end, wherein the distal end of the second tube is fixedly attached to the mid-portion of the first tube and wherein the distal end of the second tube includes a drainage aperture. A drainage lumen is defined by a space between the first tube and the second tube. A connector is attached to the proximal end of the second tube. The connector includes a reservoir for receiving a fluid from the proximal end of the second tube. The first tube extends through the connector and does not attach directly with the second tube at the connector, and the first tube remains substantially coaxial with the second tube throughout a length of the second tube. | 2016-04-07 |
| 20160095973 | Collapsible and Expandable Corrugated Hose with Directional Hand-Pump for Colon Hydrotherapy - A corrugated collapsible and expandable hose specifically for use in colon hydrotherapy which is collapsed for shipping and storage purposes and can be expanded to its full length or part of its full length for use during a colon hydrotherapy treatment and in order to accommodate specific treatment room set-ups. The invention includes a non-corrugated directional hand-pump section which allows the practitioner to apply pumping action to the hose to increase treatment efficacy. This directional hand-pump section is similar to a primer bulb but without valves to restrict direction of flow. Rather, the practitioner may fold the tubing at a crimpable indentation while squeezing the hand pump section to simultaneously stop water flow and control the direction of the pumping action. | 2016-04-07 |
| 20160095974 | Irrigation System And Clip For A Surgical Instrument - An irrigation system for a surgical instrument includes an irrigation tube arranged to convey an irrigation fluid and an irrigation clip structurally arranged to receive a portion of the irrigation tube. The irrigation clip includes a proximal portion, a distal portion, a body portion, and an arm portion. The arm portion is structurally configured to selectively attach the irrigation clip to the surgical instrument and to bias the irrigation clip toward the surgical instrument with a biasing force. The irrigation clip includes a tube locking portion structurally arranged to cooperate with the surgical instrument to engage the outer surface portion of the irrigation tube to inhibit rotation and axial displacement of the irrigation tube relative to the irrigation clip in response to the biasing force. | 2016-04-07 |
| 20160095975 | Infusion Pump System and Method - Some embodiments of an infusion pump system may be configured to provide a desired level of resistance to liquid ingress to the pump casing while contemporaneously providing air transmissibility for equalization of air pressure differentials between the interior and exterior of the pump casing. Further, some embodiments can detect when moisture inside a casing of the infusion pump system is greater than or equal to a threshold level and can initiate one or more patient safety countermeasures. | 2016-04-07 |
| 20160095976 | MANAGEMENT OF DIALYSIS AND INFUSION DATA METHODS AND APPARATUS - A networked patient care system includes an infusion pump communicatively coupled to a hospital network and configured to perform an infusion treatment on a patient, a dialysis machine communicatively coupled to the hospital network and configured to perform a dialysis treatment on the same patient, and a server communicatively coupled to the infusion pump and the dialysis machine via the hospital network. The server is configured to receive the infusion pump data, receive the dialysis machine, determine that the infusion pump data is related to the dialysis machine data, and determine a display device that is to receive the infusion pump data and the dialysis machine data. The server is further configured to transmit the infusion pump data and the dialysis machine data to the determined display device and cause the display device to display the infusion pump data and the dialysis machine data. | 2016-04-07 |
| 20160095977 | Apparatus for Dispensing Medicinal Fluids and Method of Making Same - A dispensing device and the method of making same for dispensing medicaments to a patient that includes a housing, a first assembly connected to the first end of the housing that includes a body portion, and a penetrating sub-assembly. The first assembly also includes a rate control chip of novel construction that is connected to the penetrating sub-assembly and functions to control the rate of flow of medicinal fluid to the patient. Disposed within the housing is a second assembly that includes a shuttle, a collapsible container carried by the shuttle and a plurality of variable force springs that function to thrust the collapsible container into penetrating engagement with the penetrating member of the penetrating assembly and then to collapse the collapsible container to deliver the medicinal fluid to the patient. Connected to the second end of the housing is a novel third assembly that includes an operating member that functions to controllably move the shuttle forwardly of the housing. | 2016-04-07 |
| 20160095978 | DRUG INJECTION SYRINGE - A drug injection syringe includes an injection needle assembly and a syringe body. The injection needle assembly includes an injection needle, a needle hub, an elastic body, and a fitting sleeve. The fitting sleeve accommodates the needle hub and the elastic body and has a fitting hole formed in a female taper shape. The syringe body includes an outer tube and a drug discharge tube formed in a male taper shape. The syringe body is attached to the injection needle assembly by pushing the drug discharge tube into the fitting hole by a press fitting. The elastic body couples the drug discharge tube and the injection needle in a liquid-tight manner by compressively deforming, due to the press fitting, at a protruding portion disposed on a periphery of the pocket and stretching against an inner wall of the fitting hole. | 2016-04-07 |
| 20160095979 | MEDICAMENT DELIVERY DEVICE - The present invention relates to a medicament delivery device comprising a generally tubular distal housing part ( | 2016-04-07 |
| 20160095980 | Syringe Barrel Lubricant Coverage Quality Control - A quality control method or system for determining a lubricant coverage at the inside surface of a syringe barrel is provided. The timing for the quality control is not intuitive, yet crucial for patient's safety. The pre-fill test is for a pre-filled (empty or no drug solution), yet oil lubricated, barrel. This pre-fill test needs to be performed within a certain time window immediately following the lubrication. The post-fill test is for a post-filled oil lubricated syringe barrel filled with a solution. This post-fill test needs to be performed after a certain time window has passed from the filling with the solution. The quality control methods could lead to a reduction of health-risks or avoid life-threatening situations associated with syringes that are either below or above the desired lubrication coverage. | 2016-04-07 |
| 20160095981 | Drug Delivery Device with Piston Rod Coupling - A drug delivery device adapted to receive a cartridge and comprising a housing, an expelling assembly with a threaded piston rod, a threaded nut and a drive element arranged in non-rotational engagement with the piston rod, a drive coupling actuatable between a resetting state in which the piston rod can be moved proximally, and an operational state in which the drive element can drive the piston rod distally, wherein the drive element and the threaded nut are not moved axially relative to the housing when the drive coupling is actuated. | 2016-04-07 |
